GOSSAMER BIO INC (GOSS) Stock News
NASDAQ:GOSS - Nasdaq - US38341P1021 - Common Stock - Currency: USD
GOSS Latest News, Press Relases and Analysis
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
GOSS Stock Earnings: Gossamer Bio Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gossamer Bio (NASDAQ:GOSS) just reported results for the second quarter of 2024...
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Chiesi y Gossamer Bio anuncian una colaboración global para desarrollar y comercializar seralutinib
Chiesi y Gossamer Bio anuncian una colaboración global transformadora para desarrollar y comercializar seralutinib en la hipertensión arterial pulmonar y otras...
GOSS Stock Earnings: Gossamer Bio Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gossamer Bio (NASDAQ:GOSS) just reported results for the first quarter of 2024....
Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024
GOSS Stock Earnings: Gossamer Bio Misses EPS for Q1 2024
GOSS stock results show that Gossamer Bio missed analyst estimates for earnings per share the first quarter of 2024.
GOSS Stock Earnings: Gossamer Bio Misses EPS, Misses Revenue for Q2 2024
GOSS stock results show that Gossamer Bio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gossamer Bio (NASDAQ:GOSS) just reported results for the fourth quarter of 2023...
GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023
GOSS stock results show that Gossamer Bio met analyst estimates for earnings per share the fourth quarter of 2023.
The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street
Taking a small position in these penny stocks today could have you sitting on a sizable gain by the time Wall Street starts to pile in.
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Chiesi und Gossamer Bio kündigen globale Zusammenarbeit zur Entwicklung und Vermarktung von Seralutinib bei pulmonaler arterieller Hypertonie sowie anderen Atemwegsindikationen an
Strategische Zusammenarbeit, um die Führungsposition von Chiesi im Bereich der Atemwege und die Entwicklungskompetenz von Gossamer Bio im Bereich der...
Chiesi et Gossamer Bio annoncent une collaboration mondiale transformatrice pour développer et commercialiser le séralutinib pour l'hypertension artérielle pulmonaire et d'autres indications respiratoires
Collaboration stratégique pour tirer parti de l'héritage de leadership dans les maladies respiratoires de Chiesi et de l'expertise de Gossamer Bio en matière...
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications
Strategic collaboration to leverage Chiesi's legacy of respiratory leadership and Gossamer Bio's development expertise in pulmonary hypertension. Gossamer to...
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
